Kawasaki disease（KD）is an acute self-limiting febrile disorder that mainly affects children under 5 years old.The 2024 edition of“Update on Diagnosis and Management of Kawasaki Disease：A Scientific Statement From the American Heart Association” updates and summarizes the clinical research progress related to diagnosis，acute-phase cardiac imaging examinations，and long-term management since the American Heart Association released the KD scientific statement in 2017.The new statement updates the diagnostic criteria for patients at high risk of coronary artery aneurysms in the North American population，who may benefit from more aggressive initial treatment.Advances in cardiovascular imaging technology have enhanced our ability to identify coronary artery stenosis in KD patients.The latest research on KD treatment has deepened our understanding of the safety and dosage regimens of multiple anti-inflammatory treatments for KD.The new statement also explores key clinical issues such as the application of new oral anticoagulants，management plans for myocardial infarction，selection of anti-platelet drugs，anti-coagulation treatment strategies，and methods for assessing myocardial ischemia，with particular emphasis on long-term follow-up management strategies for patients with coronary artery complications.

Kawasaki disease, diagnosis, treatment, management

川崎病是一种急性自限性发热性疾病，主要累及5岁以下儿童。2024年版《关于川崎病诊断与管理的最新进展：美国心脏协会科学声明》（简称新《声明》）更新汇总了自2017年美国心脏协会发布川崎病科学声明以来，与诊断、急性期心脏影像学检查和长期管理相关的临床研究进展。新《声明》更新了针对北美地区人群的冠状动脉瘤高风险患者的界定标准，这类患者可能受益于更积极的初始治疗。心血管影像技术的进步提高了医生对川崎病患者冠状动脉狭窄的识别能力，最新的关于川崎病治疗研究加深了临床对多种川崎病抗炎治疗安全性和剂量方案的认识。新《声明》还探讨了新型口服抗凝药物的应用、心肌梗死管理方案、抗血小板药物选择、抗凝治疗策略、心肌缺血评估方法等关键临床问题，特别强调了冠状动脉并发症患者的长期随访管理策略。

川崎病, 诊断, 治疗, 管理